BAAM
RNAM

Baker Avenue Asset Management’s Avidity Biosciences RNAM Stock Holding History

Baker Avenue Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20
Closed -$222 – 1703
2023
Q2 		$222 Buy
+20
New +$251 ﹤0.01% 1562

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Baker Avenue Asset Management's RNAM Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Avidity Biosciences (RNAM) in Q3 2023, closing a stake of 20 shares — an estimated $222 sold.

Baker Avenue Asset Management first reported a position in RNAM in Q2 2023 and held it in 1 quarter. The position peaked at $222 in Q2 2023. 142 funds tracked by Wall St. Rank hold RNAM as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Avidity Biosciences position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 20 Avidity Biosciences shares in Q3 2023, an estimated $222.
  • Baker Avenue Asset Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Avidity Biosciences position peaked at $222 in Q2 2023.
  • 142 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.